Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

429
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
429
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

257
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

534
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
534

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological Biomarkers to Assess Activity and Treatment Response in IgG4-Related Disease.

Medicina (Kaunas, Lithuania)·2026
Same author

Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis.

Cells·2025
Same author

Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice.

Diagnostics (Basel, Switzerland)·2024
Same author

Clinical and Serological Profiles in Cryoglobulinemia: Analysis of Isotypes and Etiologies.

Journal of clinical medicine·2024
Same author

Designing an integrated care pathway for spondyloarthritis: A Lean Thinking approach.

Journal of evaluation in clinical practice·2024
Same author

Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?

Journal of clinical medicine·2024

Related Experiment Video

Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Rheumatologists' perceptions of biosimilar use in Spain: the CUSTODIAN study.

Hector Corominas1,2,3,4, Marcelo Alejandro Guigini5, Yanina Susana Ameruso5

  • 1Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Current Medical Research and Opinion
|April 24, 2026
PubMed
Summary

Spanish rheumatologists view biosimilars as safe and effective for rheumatoid arthritis (RA) management. Key drivers for adoption include sustainability and cost savings, though patient concerns remain.

Keywords:
Rheumatoid arthritisbiosimilarsclinical practice patternpatient preferencerheumatologists

More Related Videos

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

3.7K
Automated Joint Space Detection Improves Bone Segmentation Accuracy
06:45

Automated Joint Space Detection Improves Bone Segmentation Accuracy

Published on: November 28, 2025

333

Related Experiment Videos

Last Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

3.7K
Automated Joint Space Detection Improves Bone Segmentation Accuracy
06:45

Automated Joint Space Detection Improves Bone Segmentation Accuracy

Published on: November 28, 2025

333

Area of Science:

  • Rheumatology
  • Pharmacoeconomics
  • Drug Development

Background:

  • Rheumatoid arthritis (RA) management relies on biologics, with biosimilars offering potential cost savings.
  • Understanding rheumatologists' perspectives is crucial for successful biosimilar integration.

Purpose of the Study:

  • To explore rheumatologists' experiences and perceptions of using biosimilars in RA management in Spain.

Main Methods:

  • A descriptive, exploratory survey study was conducted in Spain (March-April 2025).
  • Participants included 30 experienced rheumatologists (≥10 years Rheumatology, ≥5 years using RA biosimilars).
  • The 85-item survey assessed participant/patient characteristics, biosimilar use, perceptions, and patient attitudes.

Main Results:

  • Most rheumatologists initiated biosimilars in biologic-naïve patients; switching was less common.
  • Six months post-initiation/switching, disease activity remained stable or improved for most patients.
  • Biosimilars were perceived as safe and effective as reference biologics, with sustainability and cost savings as key adoption drivers.

Conclusions:

  • Biosimilars are viewed favorably by Spanish rheumatologists for RA management.
  • Addressing patient concerns and implementing educational interventions can further optimize biosimilar use.